Company Overview and News

0
Suven Life gets patents from Europe, South Korea

2018-07-16 moneycontrol
Suven Life Sciences today said it has been granted a product patent by Europe and South Korea each for a new chemical entity (NCE) used in treatment of disorders associated with neurodegenerative diseases.
530239 SUVEN

0
Suven Life Sciences Limited - Press Release

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

0
Suven Life gets product patents from India, South Korea

2018-07-04 moneycontrol
Suven Life Sciences today said it has been granted a product patent by India, Singapore, South Korea and Israel each for a new chemical entity (NCE) used in treatment of disorders associated with neurodegenerative diseases.
530239 SUVEN

0
Suven Life Sciences stock gains 3% as company secures 4 product patents

2018-07-04 moneycontrol
Shares of Suven Life Sciences gained more than 3 percent intraday on Wednesday as it has secured four product patents.
530239 SUVEN

0
Suven Life Sciences Limited - Press Release

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

0
Suven Life Sciences Limited - Updates

2018-06-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

0
Suven Life gets product patents from China, United States

2018-06-12 moneycontrol
Suven Life Sciences today said it has been granted a product patent by China and the US each for a new chemical entity (NCE) for treatment of disorders associated with neurodegenerative diseases. These patents are valid till 2034 and 2036, respectively, the company said in a BSE filing.
530239 SUVEN

0
Suven Life Sciences Limited - Press Release

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

0
Suven Life Sciences Limited - Press Release

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

26
Market Live: Sensex mildly lower; all sectoral indices in the red except Auto

2018-06-01 moneycontrol
Market Update: The market continued to be mildly under pressure amid consolidation, but European stocks are strong in trade after Italy agreed to form a government.
BAJAJ-AUTO 539150 513262 500325 GAYAPROJ RELIANCE TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 531795 505200 532343 RIGD HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 RLNIY ASHOKLEY ECQRY TVSMOTOR IBN ATULAUTO 532767 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS MARUTI 532174 HRTQY AKLS SSWL TTM

29
Market Live: Sensex mildly lower, Midcaps underperform; HDFC Bank drags, Eicher Motors dips 4%

2018-06-01 moneycontrol
Allahabad High Court on Power NPAs: Allahabad High Court has stayed the Reserve Bank of India’s February 12 circular on resolution on non-performing assets (NPAs) for the assets in the power sector.
BAJAJ-AUTO 539150 513262 GAYAPROJ TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 531795 505200 533106 OIL HDFCBANK HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 ASHOKLEY ECQRY IBN ATULAUTO 532767 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS HDB MARUTI 532174 500180 HRTQY AKLS SSWL TTM

23
Market Live: Nifty holds 10,700 amid consolidation; Bajaj Auto extends rally

2018-06-01 moneycontrol
Market Update: The market continued to be rangebound as investors digested better-than-expected Q4 GDP data, which shows India is the fastest growing economy, and shifted focus to global trade concerns, and the movement in crude oil prices & rupee.
BAJAJ-AUTO 539150 TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 505200 533106 GRANULES OIL 532482 HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 ASHOKLEY ECQRY IBN 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS MARUTI 532174 HRTQY AKLS TTM

0
Suven Life Sciences Limited - Press Release

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

0
Suven Life gets product patents from New Zealand, Norway

2018-05-22 thehindubusinessline
Suven Life Sciences on Tuesday said that it has been granted one product patent each from New Zealand and Norway corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034 and 2027, respectively.
530239 SUVEN

0
Suven Life gets product patents from New Zealand, Norway

2018-05-22 livemint
New Delhi:Suven Life Sciences on Tuesday said it has been granted a product patent by New Zealand and Norway each corresponding to a new chemical entity (NCE) for treatment of disorders associated with neurodegenerative diseases.
530239 SUVEN

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

10h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

11h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...